Introduction
Overgrowth syndromes represent a rare and heterogeneous group of genetic disorders characterized by excessive prenatal or postnatal growth. These conditions can manifest as generalized macrosomia or segmental overgrowth, where specific body regions develop disproportionately. Often, these syndromes are linked to dysregulation in growth factor signaling pathways, such as the PI3K/AKT/mTOR pathway, which inherently increases the risk of malignancy.
Thauvin-Robinet-Faivre Syndrome (TROFAS) is an exceptionally rare autosomal recessive overgrowth disorder caused by biallelic variants in the FIBP (FGF-1 intracellular binding protein) gene. Prior to this report, only eight cases had been documented globally. This case details the ninth known instance, identifying unique clinical features and significantly expanding the known oncological spectrum of the disease.
Case Presentation and Clinical Profile
The patient, a 16-year-old female, presented with a complex clinical phenotype. Notably, she did not exhibit the generalized macrosomia or tall stature seen in some other TROFAS cases, underscoring the variability of the syndrome. Instead, her presentation was dominated by segmental anomalies and intellectual disability (IQ 65).
Physical examination revealed distinctive facial dysmorphism, including a flat midface, thick lips, and synophrys. Skeletal abnormalities such as pectus excavatum and scoliosis were also present. Most strikingly, the patient exhibited significant segmental overgrowth of the hands and feet, as illustrated in the clinical photography.
Further clinical investigation identified extensive vascular involvement, including varicose veins and port-wine stains. Skin examination also revealed nodules on the extremities, further characterizing the segmental nature of the disorder.
Genomic and Pathological Findings
Whole Exome Sequencing (WES) performed on the patient and her father identified a homozygous, likely pathogenic frameshift variant in the FIBP gene: NM_004214.5 c.412-3_415dup (p.Asp139AlafsTer3). This variant likely results in a truncated, non-functional protein.
The FIBP gene product interacts with Fibroblast Growth Factors (FGFs), which are critical for cell proliferation and differentiation. The loss of functional FIBP protein is thought to dysregulate these processes, potentially through the mTOR/STAT3 pathways, providing a molecular link between the observed overgrowth and the patient's predisposition to cancer.
Oncological Significance
The most critical finding in this case is the early onset of multiple malignancies. By age 16, the patient developed both thyroid follicular carcinoma and parotid mucoepidermoid carcinoma. Previously, the only malignancy associated with TROFAS was a single reported case of Wilms' tumor. This case marks TROFAS as a condition requiring rigorous and early oncological screening, as it expands the known tumor predisposition spectrum to include head and neck carcinomas.
Discussion and Future Directions
This case highlights that TROFAS can present with normal overall height and weight while still exhibiting severe segmental overgrowth and life-threatening malignancies. The identification of thyroid and parotid carcinomas marks a significant shift in our understanding of the syndrome's risks.
Future research must focus on functional studies to elucidate the exact molecular mechanisms by which FIBP loss-of-function triggers specific cancers. Furthermore, establishing standardized clinical surveillance protocols is essential for the early detection of tumors in this vulnerable population. Given the rarity of the condition, exploring the possibility of mosaic FIBP variants in "unsolved" overgrowth cases may also yield further insights into the disease's prevalence and pathophysiology.
Summary updated